Leerink Partnrs Has Positive Outlook for Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Equities research analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for Hologic in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will post earnings of $1.06 per share for the quarter, up from their prior estimate of $1.04. The consensus estimate for Hologic's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Hologic's Q4 2025 earnings at $1.11 EPS and FY2025 earnings at $4.27 EPS.

Several other equities research analysts have also recently weighed in on HOLX. Citigroup cut shares of Hologic from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Royal Bank of Canada upped their target price on Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a report on Tuesday. StockNews.com downgraded Hologic from a "buy" rating to a "hold" rating in a report on Wednesday. Raymond James upped their price objective on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, Stephens reaffirmed an "overweight" rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $89.25.

Hologic Stock Down 1.5 %

Hologic stock traded down $1.20 during midday trading on Thursday, hitting $79.29. 1,456,026 shares of the company's stock were exchanged, compared to its average volume of 1,594,685. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The company has a market cap of $18.42 billion, a PE ratio of 23.81, a P/E/G ratio of 3.03 and a beta of 0.98. The firm has a 50-day moving average of $81.02 and a two-hundred day moving average of $78.13. Hologic has a 12 month low of $66.93 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.89 EPS.

Institutional Trading of Hologic

Institutional investors have recently bought and sold shares of the stock. Norden Group LLC lifted its stake in shares of Hologic by 44.0% during the first quarter. Norden Group LLC now owns 5,480 shares of the medical equipment provider's stock worth $427,000 after buying an additional 1,675 shares during the period. Mutual of America Capital Management LLC increased its holdings in shares of Hologic by 22.6% in the first quarter. Mutual of America Capital Management LLC now owns 40,286 shares of the medical equipment provider's stock valued at $3,141,000 after purchasing an additional 7,432 shares during the period. Central Pacific Bank Trust Division acquired a new position in shares of Hologic in the first quarter valued at about $77,000. Chevy Chase Trust Holdings LLC raised its stake in shares of Hologic by 3.7% in the first quarter. Chevy Chase Trust Holdings LLC now owns 168,375 shares of the medical equipment provider's stock worth $13,127,000 after purchasing an additional 6,077 shares during the last quarter. Finally, Empirical Finance LLC lifted its holdings in shares of Hologic by 3.2% during the first quarter. Empirical Finance LLC now owns 9,103 shares of the medical equipment provider's stock worth $710,000 after purchasing an additional 283 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.